NEW YORK, Jan 30 – Rosetta Inpharmatics said Tuesday its fourth quarter net revenues increased to $5.6 million, compared with $386,000 a year ago, due to the launch of the Rosetta Resolver Gene Expression Data Analysis System, a collaboration agreement with Monsanto, and revenues from its partnership with Agilent.

For the full year, revenues increased more than 10-fold to $10.5 million, from $983,000 in 1999.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

US Attorney General Jeff Sessions is considering using DNA tests to determine relatedness between adult and child migrants, the Daily Caller reports.

Bloomberg reports that Brainstorm Cell Therapeutics plans to offer a treatment it is developing under the "right to try" law for hundreds of thousands of dollars.

In Nature this week: expansion of disease-resistance genes among long-lived oak trees, and more.

In a proof-of-concept study, researchers report being able to determine age from dried bloodstains, Discover's D-brief blog reports.